CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models

The global disease burden of liver fibrosis remains significant. Our study provides a novel therapeutic approach, demonstrating that cell therapy targeting activated HSCs can improve liver fibrosis and HCC. These results provide an important theoretical foundation for clinicians and translational researchers. Although further studies are needed to evaluate safety and efficacy before clinical translation, this approach could ultimately offer a cell therapy option to halt disease progression in patients with advanced liver fibrosis.